Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of $0.38, Misses by 4c
ARNA Hot Sheet
Revenue Growth %: -48.1%Financial Fact:
Total interest and other expense, net: -6.97M
Today's EPS Names:
VSNT, CIM, KH, More
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reports Q3 loss of $0.38, versus the analyst estimate of ($0.34). Revenue for the quarter was $2.62 million, which compares to the estimate of $2.43 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- Signet Jewelers (SIG) Tops Q1 EPS by 5c; Guides Q2 Below the Street
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
